Zealand Pharma A/S
ZEALDrugs in Pipeline
54
Phase 3 Programs
36
Upcoming Catalysts
7
Next Catalyst
This month
Market Overview
Stock performance and key metrics
7 upcoming, 1 past
GlucaGen
Hypoglycemia
Pantoprazole
Gastrointestinal Hemorrhage (Clinically Important, Upper)
Gentamicin, Cefazolin and Vancomycin
Implant Complication
Aspirin
Venous Leg Ulcer
Letrozole
Infertility
Moxifloxacin or Levofloxacin
Community-acquired Pneumonia, Influenza, COVID-19
Bleomycin (active name: Bleomycin Sulfate)
Germ Cell Tumor
Preoperative chemotherapy
Retroperitoneal Sarcoma
NSAA
Prostatic Neoplasms
Methylprednisolone 250 mg
STEMI - ST Elevation Myocardial Infarction
Darolutamide
Prostate Cancer
SR-A + Epratuzumab
Acute Lymphoblastic Leukemia (ALL)
Rapid sedation
Non-Convulsive Status Epilepticus
VP16
Acute Lymphoblastic Leukaemia
triptorelin
Breast Cancer
GDMT
Heart Failure With Reduced Ejection Fraction
Conventional NSAA
Prostatic Neoplasms
6% Hydroxy-ethyl starch (130/0.4)
Intensive Care
Plasma-Lyte 148 (approx. pH 7.4) IV Infusion
End Stage Kidney Disease
Glepaglutide
Short Bowel Syndrome
dasiglucagon
Hypoglycemia
Glepaglutide 10 mg
Short Bowel Syndrome (SBS)
Melatonin (N-acetyl-5-methoxytryptamine)
Depression
Methoxyflurane
Cancer
Epoetin Alfa
Traumatic Brain Injury
Fibrinogen Concentrate
Trauma
acetylsalicyclic acid (ASA)
Covert Brain Infarction
Dexamethasone Oral
Rheumatic Fever
Nicotine patch
Smoking Cessation
Epoetin Alfa 40000 UNT/ML
Trauma
Aspirin tablet
Cardiovascular Diseases
Tranexamic Acid
Wounds and Injuries
Bacillus Calmette-Guerin Vaccine Intravesical
Transitional Cell Carcinoma
Selinexor
Endometrial Cancer
LMWH (Fragmin, dalteparin)
Critical Illness
Heparin
Pulmonary Embolism
Petrelintide
Obesity
danegaptide
Focus of Study is STEMI
Bortezomib
Acute Lymphoblastic Leukemia (ALL)
therapeutic endoscopy with metronidazole and fosfomycin disodium
Right-sided Colon Cancer
ZP4207(dasiglucagon) glucagon analogue
Diabetes Mellitus Type 1
ZP1848
Short Bowel Syndrome
Insulin Lispro
Diabetes Mellitus, Type 1
Dapiglutide
Obesity
ZP4207
Hypoglycemia
Anakinra (Kineret®)
Premature Infants
red blood cell transfusion
Atherosclerosis
Incobotulinumtoxin-A 100 UNIT Injection
Diabetic Neuropathy, Painful
Anakinra
Prematurity; Extreme
Denosumab
Gout
Omalizumab Injection
Asthma
dexamethasone phosphate
Suspected Appendicitis
AndroGel
Hypogonadism
177Lu-PSMA-617
Metastatic Hormone Naive Prostate Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GlucaGen | Phase 3 | Hypoglycemia | - | - |
Pantoprazole | Phase 3 | Gastrointestinal Hemorrhage (Clinically Important, Upper) | - | - |
Gentamicin, Cefazolin and Vancomycin | Phase 3 | Implant Complication | - | - |
Aspirin | Phase 3 | Venous Leg Ulcer | - | - |
Letrozole | Phase 3 | Infertility | - | - |
Moxifloxacin or Levofloxacin | Phase 3 | Community-acquired Pneumonia, Influenza, COVID-19 | - | - |
Bleomycin (active name: Bleomycin Sulfate) | Phase 3 | Germ Cell Tumor | - | - |
Preoperative chemotherapy | Phase 3 | Retroperitoneal Sarcoma | - | - |
NSAA | Phase 3 | Prostatic Neoplasms | - | - |
Methylprednisolone 250 mg | Phase 3 | STEMI - ST Elevation Myocardial Infarction | - | - |
Darolutamide | Phase 3 | Prostate Cancer | - | - |
SR-A + Epratuzumab | Phase 3 | Acute Lymphoblastic Leukemia (ALL) | - | - |
Rapid sedation | Phase 3 | Non-Convulsive Status Epilepticus | - | - |
VP16 | Phase 3 | Acute Lymphoblastic Leukaemia | - | - |
triptorelin | Phase 3 | Breast Cancer | - | - |
GDMT | Phase 3 | Heart Failure With Reduced Ejection Fraction | - | - |
Conventional NSAA | Phase 3 | Prostatic Neoplasms | - | - |
6% Hydroxy-ethyl starch (130/0.4) | Phase 3 | Intensive Care | - | - |
Plasma-Lyte 148 (approx. pH 7.4) IV Infusion | Phase 3 | End Stage Kidney Disease | - | - |
Glepaglutide | Phase 3 | Short Bowel Syndrome | - | - |
dasiglucagon | Phase 3 | Hypoglycemia | - | - |
Glepaglutide 10 mg | Phase 3 | Short Bowel Syndrome (SBS) | - | - |
Melatonin (N-acetyl-5-methoxytryptamine) | Phase 3 | Depression | - | - |
Methoxyflurane | Phase 3 | Cancer | - | - |
Epoetin Alfa | Phase 3 | Traumatic Brain Injury | - | - |
Fibrinogen Concentrate | Phase 3 | Trauma | - | - |
acetylsalicyclic acid (ASA) | Phase 3 | Covert Brain Infarction | - | - |
Dexamethasone Oral | Phase 3 | Rheumatic Fever | - | - |
Nicotine patch | Phase 3 | Smoking Cessation | - | - |
Epoetin Alfa 40000 UNT/ML | Phase 3 | Trauma | - | - |
Aspirin tablet | Phase 3 | Cardiovascular Diseases | - | - |
Tranexamic Acid | Phase 3 | Wounds and Injuries | - | - |
Bacillus Calmette-Guerin Vaccine Intravesical | Phase 3 | Transitional Cell Carcinoma | - | - |
Selinexor | Phase 3 | Endometrial Cancer | - | - |
LMWH (Fragmin, dalteparin) | Phase 3 | Critical Illness | - | - |
Heparin | Phase 3 | Pulmonary Embolism | - | - |
Petrelintide | Phase 2 | Obesity | - | - |
danegaptide | Phase 2 | Focus of Study is STEMI | - | - |
Bortezomib | Phase 2 | Acute Lymphoblastic Leukemia (ALL) | - | - |
therapeutic endoscopy with metronidazole and fosfomycin disodium | Phase 2 | Right-sided Colon Cancer | - | - |
ZP4207(dasiglucagon) glucagon analogue | Phase 2 | Diabetes Mellitus Type 1 | - | - |
ZP1848 | Phase 2 | Short Bowel Syndrome | - | - |
Insulin Lispro | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
Dapiglutide | Phase 2 | Obesity | - | - |
ZP4207 | Phase 2 | Hypoglycemia | - | - |
Anakinra (Kineret®) | Phase 2 | Premature Infants | - | - |
red blood cell transfusion | Phase 2 | Atherosclerosis | - | - |
Incobotulinumtoxin-A 100 UNIT Injection | Phase 2 | Diabetic Neuropathy, Painful | - | - |
Anakinra | Phase 2 | Prematurity; Extreme | - | - |
Denosumab | Phase 2 | Gout | - | - |
Omalizumab Injection | Phase 2 | Asthma | - | - |
dexamethasone phosphate | Phase 2 | Suspected Appendicitis | - | - |
AndroGel | Phase 2 | Hypogonadism | - | - |
177Lu-PSMA-617 | Phase 2 | Metastatic Hormone Naive Prostate Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Zealand Pharma A/S's drug pipeline?→
CatalystAlert tracks 54 drug candidates in Zealand Pharma A/S's (ZEAL) pipeline across Phase 3, Phase 2. Its lead program is GlucaGen (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Zealand Pharma A/S's next FDA catalyst?→
Zealand Pharma A/S's (ZEAL) next tracked catalyst is a Phase 3 expected September 26, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ZEAL biotech catalysts?→
Add ZEAL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Zealand Pharma A/S's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.